Compare Regeneron Pharmaceuticals Inc (REGN) vs Energy Select Sector SPDR Fund (XLE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Energy Select Sector SPDR Fund — how do they compare? Regeneron Pharmaceuticals Inc trades at $808.33 (market cap $83.15B), while Energy Select Sector SPDR Fund trades at $65.59. The key difference: Regeneron Pharmaceuticals Inc pays a 0.47% dividend while Energy Select Sector SPDR Fund pays none, and Energy Select Sector SPDR Fund is trading nearer its 52-week high, Regeneron Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| REGN | XLE | |
|---|---|---|
Market Cap | $83.15B | — |
Sector | Health | — |
52-Week High | $852.03 | $65.31 |
52-Week Low | $555.51 | $42.61 |
Enterprise Value | $77.86B | — |
Dividend Yield | 0.47% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $810.31, down 2.1% on the day, with a bullish technical signal from moving averages and a neutral RSI near 54. The stock shows strong profitability with a net income margin of 27.86% and consistent earnings beats in recent quarters. However, multiple class-action lawsuits filed in September 2026 allege securities fraud related to a Phase 3 clinical trial disclosure, creating near-term uncertainty.
The outlook remains cautiously optimistic given robust fundamentals and a 69% analyst buy rating, but legal overhangs and a projected earnings dip in 2026 pose risks. Upside hinges on legal resolution and pipeline execution, while downside is capped by institutional support like CalSTRS' recent $79 billion position increase.
XLE, the Energy Select Sector SPDR ETF, trades at $64.78, up 1.12% amid bullish technical signals and strong sector momentum. The ETF benefits from rising oil prices, with Brent crude exceeding $100 per barrel due to Middle East tensions, as reported by Reuters on September 9, 2026. Technical indicators show a bullish moving average consensus, though the 6-day RSI at 78.15 suggests potential overbought conditions. Recent performance includes a 7.4% gain in August, leading sector ETFs, per ETF Trends on September 2, 2026.
Outlook remains positive driven by geopolitical supply risks and institutional optimism, with Goldman Sachs forecasting oil could reach $120 (Zacks, September 8, 2026). Key risks include oil price volatility and refining capacity constraints. The ETF's concentration in large caps like Exxon and Chevron offers stability, but investors face exposure to energy market cyclicality.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Energy Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies that have been identified as energy companies by the GICS®, including securities of companies from the following industries: oil, gas and consumable fuels; and energy equipment and services. It is non-diversified.
Read more on XLE →
